‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study
A. Michils, O. Vandenplas, G. Brusselle, C. Lee, J. Van Schoor, S. Gurdain, C. Hermans, S. Vancayzeele, K. MacDonald, I. Abraham (Brussels, Yvoir, Ghent, Vilvoorde, Belgium; Earlysville, Oregon, Tucson, United States Of America)
Source: Annual Congress 2011 - Asthma management and response
Session: Asthma management and response
Session type: Thematic Poster Session
Number: 3959
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Michils, O. Vandenplas, G. Brusselle, C. Lee, J. Van Schoor, S. Gurdain, C. Hermans, S. Vancayzeele, K. MacDonald, I. Abraham (Brussels, Yvoir, Ghent, Vilvoorde, Belgium; Earlysville, Oregon, Tucson, United States Of America). ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study. Eur Respir J 2011; 38: Suppl. 55, 3959
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: